Rothschild & Co Redburn Predicts Biogen Q1 Earnings

Key Points

• Rothschild & Co Redburn forecasts Q1 2026 EPS of $3.51, kept a Neutral rating with a $180 price target, and issued Q2–Q4 EPS estimates of $4.73, $4.42 and $3.33; market consensus for full‑year EPS is about $15.75 and Biogen’s FY2026 guidance is 15.25–16.25.
• Analyst sentiment is mixed — upgrades from Piper Sandler, Guggenheim and UBS have raised price targets (up to $246), while Wolfe Research and HSBC cut estimates or stayed cautious, leaving an average target near $211 and a MarketBeat consensus of "Hold".
• Shares trade around $188 (market cap ≈ $27.6B, P/E ~21.3); insiders recently sold stock and institutional investors own roughly 87.9% of Biogen, indicating concentrated institutional ownership.

Biogen Inc. (NASDAQ:BIIB - Free Report) - Rothschild & Co Redburn issued their Q1 2026 earnings per share (EPS) estimates for shares of Biogen in a research note issued on Tuesday, April 21st. Rothschild & Co Redburn analyst S. Chesney anticipates that the biotechnology company will earn $3.51 per share for the quarter. Rothschild & Co Redburn has a "Neutral" rating and a $180.00 price target on the stock. The consensus estimate for Biogen's current full-year earnings is $15.75 per share. Rothschild & Co Redburn also issued estimates for Biogen's Q2 2026 earnings at $4.73 EPS, Q3 2026 earnings at $4.42 EPS and Q4 2026 earnings at $3.33 EPS.

A number of other analysts also recently commented on BIIB. Argus raised Biogen to a "hold" rating in a research report on Thursday, April 9th. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Biogen in a research report on Monday, December 29th. Piper Sandler raised Biogen from a "neutral" rating to an "overweight" rating and increased their price target for the company from $177.00 to $214.00 in a research report on Tuesday, April 14th. Guggenheim increased their price target on Biogen from $185.00 to $246.00 and gave the company a "buy" rating in a research report on Monday, February 9th. Finally, Royal Bank Of Canada decreased their price target on Biogen from $233.00 to $213.00 and set an "outperform" rating for the company in a research report on Tuesday, April 7th. Fourteen research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Biogen currently has an average rating of "Hold" and an average target price of $211.31.

Biogen Trading Down 1.2%

NASDAQ BIIB opened at $187.88 on Friday. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34. The firm has a market capitalization of $27.57 billion, a P/E ratio of 21.33, a PEG ratio of 2.54 and a beta of 0.16. The business has a fifty day simple moving average of $185.37 and a 200 day simple moving average of $174.82. Biogen has a 12 month low of $115.25 and a 12 month high of $202.41.

Biogen (NASDAQ:BIIB - Get Free Report) last released its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, beating analysts' consensus estimates of $1.61 by $0.38. The business had revenue of $2.28 billion during the quarter, compared to analyst estimates of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.Biogen's quarterly revenue was down 7.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS.

Institutional Investors Weigh In On Biogen

Several large investors have recently added to or reduced their stakes in BIIB. Convergence Investment Partners LLC bought a new position in shares of Biogen in the third quarter worth $1,342,000. Caprock Group LLC bought a new position in shares of Biogen in the third quarter worth $742,000. Leuthold Group LLC bought a new position in shares of Biogen in the third quarter worth $3,294,000. Generali Investments Management Co LLC boosted its holdings in shares of Biogen by 408.2% in the third quarter. Generali Investments Management Co LLC now owns 9,970 shares of the biotechnology company's stock worth $1,397,000 after acquiring an additional 8,008 shares during the period. Finally, CWM LLC boosted its holdings in shares of Biogen by 36.4% in the third quarter. CWM LLC now owns 47,455 shares of the biotechnology company's stock worth $6,648,000 after acquiring an additional 12,673 shares during the period. Hedge funds and other institutional investors own 87.93% of the company's stock.

Insiders Place Their Bets

In related news, insider Priya Singhal sold 2,660 shares of Biogen stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the sale, the insider owned 8,043 shares of the company's stock, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.18% of the company's stock.

Key Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: UBS upgraded BIIB to Buy and raised its price target to $225 (from $185), citing a "slew of pipeline catalysts" over the next 12–15 months that could drive material upside. This is the primary bullish driver supporting higher share prices. Article Title
• Neutral Sentiment: JPMorgan raised its price target on BIIB to $185 (from $175) but kept a Neutral rating — a modest technical upward revision that signals limited near-term conviction despite a higher target. Article Title
• Neutral Sentiment: Rothschild & Co. Redburn raised its price target to $180 (from $150) and published quarterly EPS breakouts (Q1–Q4 2026 estimates), while maintaining a Neutral rating — incremental data for modeling but not a clear buy signal. Article Title
• Neutral Sentiment: Public mentions (e.g., Jim Cramer citing reopened coverage after a Wells Fargo take) add retail visibility but are not a fundamental catalyst; they may boost trading volume without changing earnings trajectory. Article Title
• Negative Sentiment: Wolfe Research cut near-term EPS estimates: Q1 2026 forecast lowered (to $2.64) and Q2 2026 EPS cut materially (to $3.78 from $4.32). Those downgrades reduce near-term earnings visibility and are a key reason for downward pressure.
• Negative Sentiment: HSBC maintains a Reduce rating with a $150 price target and longer-term FY2026–FY2029 EPS projections that imply more caution on valuation and growth — a bearish signal for investors focused on safety and downside protection.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.